Capstone Investment Advisors LLC Makes New Investment in Enliven Therapeutics, Inc. $ELVN

Capstone Investment Advisors LLC purchased a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,577 shares of the company’s stock, valued at approximately $537,000.

Several other hedge funds also recently modified their holdings of the business. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the first quarter worth $38,000. BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Enliven Therapeutics during the 4th quarter valued at $83,000. Quantbot Technologies LP boosted its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Enliven Therapeutics in the 4th quarter valued at $95,000. 95.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the sale, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 196,849 shares of company stock valued at $11,344,257 over the last quarter. Corporate insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ELVN. Mizuho boosted their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Barclays began coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 target price on the stock. Stifel Nicolaus boosted their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Guggenheim cut their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Enliven Therapeutics Price Performance

ELVN opened at $57.86 on Friday. The company has a market capitalization of $4.24 billion, a P/E ratio of -34.65 and a beta of 0.27. The firm’s fifty day moving average price is $54.62 and its two-hundred day moving average price is $43.10. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.